yantil 4 mg/ml oraaliliuos
grünenthal gmbh - tapentadoli hydrochloridum - oraaliliuos - 4 mg/ml - tapentadoli
yantil 20 mg/ml oraaliliuos
grünenthal gmbh - tapentadoli hydrochloridum - oraaliliuos - 20 mg/ml - tapentadoli
acrescent
h. lundbeck a/s - memantine hydrochloride, donepetsiilihydrokloridi - alzheimerin tauti - treatment of alzheimers disease.
balaxur
merz pharmaceuticals gmbh - memantine hydrochloride, donepetsiilihydrokloridi - alzheimerin tauti
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiset aineet - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
cometriq
ipsen pharma - cabozantinib - kilpirauhasen vajaatoiminta - antineoplastiset aineet - aikuisten potilaiden, joilla on progressiivinen, levottomuus paikallisesti edenneen tai metastaattisen keskivaikean kilpirauhaskarsinooman hoitoon.
yantil depot 50 mg depottabletti
grünenthal gmbh - tapentadoli hydrochloridum - depottabletti - 50 mg - tapentadoli
yantil depot 100 mg depottabletti
grünenthal gmbh - tapentadoli hydrochloridum - depottabletti - 100 mg - tapentadoli
yantil depot 150 mg depottabletti
grünenthal gmbh - tapentadoli hydrochloridum - depottabletti - 150 mg - tapentadoli
yantil depot 200 mg depottabletti
grünenthal gmbh - tapentadoli hydrochloridum - depottabletti - 200 mg - tapentadoli